Beijing-Based Biopharma Nordland Bioscience, Valued at $9.2 Billion, Files for Hong Kong IPO
Northland
Innovative Biopharmaceutical Manufacturer
▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators SummitScan to register
Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Comments are welcome to point out any issues. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
PharmaCircleLearned: Recently,Northland stated that in order to further enhance the company's international level, brand image, and reputation, make better use of domestic and overseas financing platforms, raise funds for the company’s long-term stable development, and strengthen its overall strength, the company, based on its overall development strategy and operational needs, plans to issue shares (H shares) overseas and apply for listing on the Hong Kong Stock Exchange. As of the time of writing, its market value was 6.613 billion yuan.
The company's current core research and development products include: Cedominji Injection, which has preliminarily demonstrated clinical translational value in the treatment of critical limb ischemia (CLTI). This is the recombinant human hepatocyte growth factor naked plasmid injection (code name NL003) under development; a New Drug Application (NDA) has been submitted.
In addition, there are recombinant protein drugs under development. IL-11 has entered the phase III clinical stage.
Reference:
NMPA/CDE；
https://www.northland-bio.com/；
Moxie Pharma Database, https://pharma.bcpmdata.com/;
FDA/EMA/PMDA；
https://www.northland-bio.com/news_detailed/7.html；
Relevant companies' public disclosures (unless otherwise noted, images in the text are from the companies' official websites);
; etc.
Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceuticals industry with the mission of "enabling the unrestricted flow of intelligence and networks." It builds a comprehensive empowerment system covering the entire pharmaceutical industry chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connectivity, industry think tanks, and ecosystem communities—it creates the infrastructure for the flow of pharmaceutical value in China.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.
